959121-99-4

Basic information

• Product Name: 3-BROMO-7-METHOXYQUINOLINE
• Synonyms: 3-BROMO-7-METHOXYQUINOLINE
• CAS NO: 959121-99-4
• Molecular Formula: C₁₀H₈BrNO
• Molecular Weight: 238.083
• Mol File: 959121-99-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 318.3 °C at 760 mmHg
• Flash Point: 146.3 °C
• Appearance: /
• Density: 1.516 g/cm³
• Vapor Pressure: 0.000681mmHg at 25°C
• Refractive Index: 1.64
• Storage Temp.: 2-8°C
• PKA: 2.85±0.25(Predicted)
• CAS DataBase Reference: 3-BROMO-7-METHOXYQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-7-METHOXYQUINOLINE(959121-99-4)
• EPA Substance Registry System: 3-BROMO-7-METHOXYQUINOLINE(959121-99-4)

Safety Data

• Hazardous Substances Data: 959121-99-4(Hazardous Substances Data)

Usage

General Description

3-Bromo-7-methoxyquinoline is an organic compound with the molecular formula C10H8BrNO. It is a quinoline derivative with a bromine atom located at the 3-position and a methoxy group at the 7-position. This chemical is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used as a building block in the production of heterocyclic compounds. 3-Bromo-7-methoxyquinoline exhibits various biological activities and is being studied for its potential therapeutic applications. It is important to handle this chemical with care as it is flammable and may cause irritation to the skin and eyes.

InChI:InChI=1/C10H8BrNO/c1-13-9-3-2-7-4-8(11)6-12-10(7)5-9/h2-6H,1H3

Upstream product

• 2065-75-0 2-Bromo-malonaldehyde 
• 536-90-3 m-Anisidine 
• 4964-76-5 7-methoxyquinoline 
• 30450-62-5 7-nitro-1,2,3,4-tetrahydro-quinoline 
• 124-41-4 sodium methylate 

Downstream Products

• 1017860-10-4 7-methoxy-3-(3-methoxyphenyl)quinoline 
• 1383379-86-9 4-(7-methoxyquinolin-3-yl)benzoic acid 
• 1383379-65-4 4-(7-hydroxyquinolin-3-yl)benzoic acid 

Relevant articles and documents

Synthetic method of 3-bromo-7-methoxyl quinoline

The invention provides a synthetic method of 3-bromo-7-methoxyl quinoline. The synthetic method of 3-bromo-7-methoxyl quinoline comprises the following steps: 1) adding a solvent into 7-nitryl-1,2,3,4-tetrahydroquinoline, adding DDQ and stirring the mixture to react to obtain 7-nitryl quinoline, wherein the molar ratio of 7-nitryl-1,2,3,4-tetrahydroquinoline and DDQ is 1: (1-5); 2) adding the solvent into 7-nitryl quinoline, heating the mixture, adding N-bromo-succinimide to react to obtain 3-bromo-7-nitryl quinoline in an insulating manner; and 3) dissolving 3-bromo-7-nitryl quinoline in thesolvent, adding sodium methylate, and heating the mixture to stir and react to obtain 3-bromo-7-methoxyl quinoline. The synthetic method of 3-bromo-7-methoxyl quinoline is concise in synthetic route,reasonable in process selection, low in raw material cost, simple and easy, convenient to operate and post-treat, high in total yield and easy to amplify.

NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: Potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases

Human 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) catalyzes the reduction of the weak estrogen estrone (E1) to the highly potent estradiol (E2). This reaction takes place in the target cell where the estrogenic effect is exerted via the estrogen receptor (ER). Estrogens, especially E2, are known to stimulate the proliferation of hormone-dependent diseases. 17β-HSD1 is overexpressed in many breast tumors. Thus, it is an attractive target for the treatment of these diseases. Ligand- and structure-based drug design led to the discovery of novel, selective, and potent inhibitors of 17β-HSD1. Phenyl-substituted bicyclic moieties were synthesized as mimics of the steroidal substrate. Computational methods were used to obtain insight into their interactions with the protein. Compound 5 turned out to be a highly potent inhibitor of 17β-HSD1 showing good selectivity (17β-HSD2, ERα and β), medium cell permeation, reasonable metabolic stability (rat hepatic microsomes), and little inhibition of hepatic CYP enzymes.